Search the Newsreel

ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm

The Rosen Law Firm has filed a class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR) on behalf of investors who purchased securities between March 20, 2025, and July 2, 2026. The lawsuit alleges that an Alarum Technologies subsidiary, NetNut, engaged in illegal activity …

Do Softer Q2 2026 Results Shift the Earnings Narrative for Valaris (VAL)?

EREGLI DEMIR CELIK Hisse Senedi Canlı Grafik

Insider Selling: Alarm.com (NASDAQ:ALRM) CFO Sells 5,400 Shares of Stock

Alarm.com (NASDAQ:ALRM) CFO Kevin Christopher Bradley sold 5,400 shares of the company's stock for $297,378, reducing his ownership by 6.46%. The company recently reported strong quarterly earnings, beating estimates with $0.77 EPS and 9.2% revenue growth. Despite the insider selling, analysts have a consensus …

Alarm.com (ALRM) CFO Bradley sells 5,400 shares in open-market trade

Alarm.com Holdings, Inc. CFO Kevin Christopher Bradley sold 5,400 shares of common stock on August 12, 2026, at a weighted average price of $55.07 per share. Following this transaction, Bradley directly holds 78,222 shares of the company's common stock. The sale, reported in a …

Disciplined Growth Investors (ALRM) discloses 7.3% Alarm.com stake

Disciplined Growth Investors, Inc. has reported a beneficial ownership of 7.3% in Alarm.com Holdings, Inc., equating to 3,585,614 shares of common stock as of June 30, 2026. The firm holds sole voting power over 3,377,527 shares and sole dispositive power over all 3,585,614 shares, …

DYO BOYA FABRİKALARI SANAYİ VE TİCARET A.Ş.(DYOBY) Sorumluluk Beyanı (Konsolide) 13 Ağustos 2026

BIZIM MAGAZALARI Hisse Senedi Canlı Grafik

Kaplan Fox Reminds Investors of Alarum Technologies Ltd. (NASDAQ: ALAR) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026

Kaplan Fox & Kilsheimer LLP has announced a securities class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR) for investors who purchased securities between March 20, 2025, and July 2, 2026. The lawsuit alleges that Alarum's subsidiary, NetNut, engaged in illegal activity by using …

Alarm.com (ALRM) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Stephen S. Trundle Chief Financial Officer - Kevin Bradley Investor Relations - Matthew Zartman Full Conference Call Transcript Operator: Good day, and thank you …

Equity in earnings of Alara Resources Limited TEMP – ASX:AUQN

Alarum Technologies (ALAR) faces added discovery motion and new U.S. class action

Alarum Technologies (ALAR) has reported new legal challenges, including an Additional Discovery Motion served on August 10, 2026, in an Israeli court and a U.S. class action complaint filed on August 5, 2026, in New Jersey. The Israeli motion, similar to an earlier one, …

Valaris (VAL) Reports Softer Earnings, Is The Stock Still Cheap?

Valaris (VAL) reported softer Q2 2026 earnings with lower revenue and net income compared to the previous year, despite strong year-to-date and one-year share price returns. The stock is considered overvalued by some fair value estimates, trading above the average analyst price target, although …

ALCAR Hisse Analizi | Alarko Carrier Teknik Ve Temel Değerlendirme, Gelecek Beklentileri Philadelphia Airport Passenger Currency Confiscation (Gdi3JidNLQ)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alarum Technologies Ltd. of Class Action Lawsuit and Upcoming Deadlines - ALAR

Pomerantz LLP has announced a class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR) for alleged securities fraud. Investors who suffered losses on their Alarum securities purchased during the Class Period have until October 5, 2026, to apply to be appointed as Lead Plaintiff. …

Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program

Kalaris Therapeutics announced its Q2 2026 financial results, reporting $93.5 million in cash, cash equivalents, and marketable securities, projected to fund operations into Q4 2027. The company is advancing its phase 1b/2 study of TH103 for neovascular age-related macular degeneration (AMD), with preliminary data …

Oak Hill Advisors (VAL) discloses 3.0M-share Valaris stake at 4.38%

Oak Hill Advisors reported a beneficial ownership of 3,038,600 common shares in Valaris Ltd, representing a 4.38% stake. This stake gives them shared voting and dispositive power over the shares, calculated based on Valaris's 69,435,807 shares outstanding as of July 30, 2026. The filing …

ALAR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alarum Technologies Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Alarum Technologies Ltd. (NASDAQ:ALAR) and its officers. The lawsuit alleges that Alarum Technologies made materially false and misleading statements, specifically regarding an alleged illegal activity by its subsidiary, NetNut, which linked customer …

Stockholder of ALRM (NASDAQ: ALRM) plans 5,400-share sale after prior disposals

A stockholder of Alarm.com Holdings, Inc. (ALRM), Kevin Bradley, has filed a notice to sell up to 5,400 shares of common stock with an aggregate market value of $297,371.52. This proposed sale relates to previously issued restricted stock awards and follows prior sales of …

Alarum Technologies, Ltd. (ALAR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz have announced a securities fraud class action lawsuit against Alarum Technologies, Ltd. (ALAR) on behalf of investors who suffered losses. The lawsuit alleges that between March 20, 2025, and July 2, 2026, the company made false statements …

Shareholders who lost money in shares of Alarum Technologies Ltd. (NASDAQ: ALAR) should contact Wolf Haldenstein Immediately Lead Plaintiff Deadline October 5, 2026

Wolf Haldenstein Adler Freeman & Herz LLP has filed a securities class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR) on behalf of investors who purchased shares between March 20, 2025, and July 2, 2026. The lawsuit alleges that Alarum failed to disclose that …

Shareholders who lost money in shares of Alarum Technologies Ltd. (NASDAQ: ALAR) should contact Wolf Haldenstein Immediately

Wolf Haldenstein Adler Freeman & Herz LLP has filed a securities class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR) on behalf of investors who purchased shares between March 20, 2025, and July 2, 2026. The lawsuit alleges that Alarum failed to disclose that …

ALRM Q2 Deep Dive: Commercial, Energy, and International Segments Drive Upward Guidance

ALRM Q2 Deep Dive: Commercial, Energy, and International Segments Drive Upward Guidance Smart property technology provider Alarm.com (NASDAQ:ALRM) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.2% year on year to $277.7 million. The company's full-year revenue guidance of …

Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary

Kalaris Therapeutics, Inc. reported a net loss of $(11.5M) for 2Q 2026, which was essentially flat compared to the previous year, while diluted loss per share improved to $(0.48). The company has no product revenue, with results primarily driven by research and development, and …

Oyak Cimento Fabrikalari AS (OYAKC) Finans Oranları

Kaplan Fox Encourages Investors of Alarum Technologies Ltd. (NASDAQ: ALAR) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR) on behalf of investors who purchased securities between March 20, 2025, and July 2, 2026. The lawsuit alleges that Alarum's subsidiary, NetNut, engaged in illegal activity by …

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kalaris Therapeutics announced its Q2 2026 financial results, including $93.5 million in cash expected to fund operations into Q4 2027. The company is currently dosing patients in a Phase 1b/2 study for TH103, a treatment for neovascular Age-related Macular Degeneration, with preliminary data anticipated …

Alarum Investors Face October Lawsuit Deadline

A federal securities class action has been filed against Alarum Technologies Ltd. (NASDAQ: ALAR) following a significant decline in its American depositary shares. The lawsuit alleges that Alarum and its executives made false or misleading statements regarding its NetNut subsidiary, specifically concerning the alleged …

Bronstein, Gewirtz & Grossman LLC Urges Alarum Technologies Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Alarum Technologies Ltd. (NASDAQ: ALAR), alleging that the company's subsidiary, NetNut, engaged in illegal activity by using customer internet devices without consent. This alleged activity exposed Alarum to significant legal and business …

ALRM vs. ASAZY: Which Stock Is the Better Value Option?

Investors interested in Security and Safety Services stocks are likely familiar with Alarm.com Holdings (ALRM) and Assa Abloy AB (ASAZY). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. …

ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Alarum Technologies Ltd. (ALAR) for securities fraud, covering the period from March 20, 2025, to July 2, 2026. The lawsuit alleges that Alarum's NetNut subsidiary linked customer devices to other networks …

Kalaris Therapeutics Releases Q2 2026 Financial Results

Kalaris Therapeutics, Inc. (ALVR) reported a narrower loss for the second quarter of 2026, with a loss of $0.48 per share, improving 21.3% from the previous year. The company's net loss for the quarter was $11.5M, reflecting ongoing efforts to manage operating expenses while …

Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results